Sparsentan (FILSPARI™)

About Travere Therapeutics

Travere Therapeutics is a publicly traded biopharma company singularly focused on rare diseases, particularly in nephrology and metabolism. Its strategic pipeline includes the commercially available therapy for IgA nephropathy and late-stage investigational candidates for FSGS and classical homocystinuria, aiming to set new standards of care. The company operates with a deep sense of urgency, guided by its 'In Rare For Life' ethos and a leadership team that includes rare disease patients and survivors, fostering strong community and advocacy partnerships.

Therapeutic Areas

Other IgA Nephropathy (IgAN) Drugs